Celestial Biolabs (BOM:532871) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Celestial Biolabs Debt-to-Equity?

Celestial Biolabs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Celestial Biolabs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Celestial Biolabs's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Celestial Biolabs's Debt-to-Equity or its related term are showing as below:

BOM:532871' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.16 Max: 4.34
Current: 4.34

During the past 13 years, the highest Debt-to-Equity Ratio of Celestial Biolabs was 4.34. The lowest was 0.08. And the median was 0.16.

BOM:532871's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs BOM:532871: 4.34

Celestial Biolabs Debt-to-Equity Historical Data

The historical data trend for Celestial Biolabs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celestial Biolabs Debt-to-Equity Chart

Celestial Biolabs Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.13

2.86

3.00

3.45

4.34

Celestial Biolabs Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	3.68	N/A	4.34	N/A

Competitive Comparison of Celestial Biolabs's Debt-to-Equity

For the Biotechnology subindustry, Celestial Biolabs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celestial Biolabs's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celestial Biolabs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Celestial Biolabs's Debt-to-Equity falls into.

Celestial Biolabs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Celestial Biolabs's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(30.533	+	89.774)	/	27.737
	=	4.34

Celestial Biolabs's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Celestial Biolabs (BOM:532871) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Celestial Biolabs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Celestial Biolabs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Celestial Biolabs (BOM:532871) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestial Biolabs Ltd (BOM:532871) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Plot No. 59, Road No 12, TSIIC Tech Park, IDA Nacharam, Hyderabad, TG, IND, 500076

Website

http://www.celestialbiolabs.com

Celestial Biolabs Ltd is an India based biopharmaceutical company. It is engaged in the business activity producing and supplying of the biotechnological products. The company offers herbal, feed supplement and nutraceutical products. The proprietary herbal products of the group include BIOVITA, CADALMIN GAE, CEL-DIGEST, BIOLIV, RHUMACEL, CEL-CLEAR, Trem Plus, O-KOF, BIOPOWER GOLD, BIO-DNORM, DERMACEL, GYNOCEL, HEALTHONE, RELIFIN, and C-KAPS. The organization formulates and manufactures Ayurvedic proprietary products for the Indian market.

Celestial Biolabs (BOM:532871) Headlines

No Headlines